A Dose-Escalation Study of Regorafenib in mCRC

Results from the DESTINY-CRC02 study showed that the lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Results from the phase 2b HERIZON-BTC-01 trial presented at ASCO reveal positive efficacy and safety in patient with advanced biliary tract cancer who received zanidatamab.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

In an interview with Targeted Oncology, Narissa Nonzee, PhD, discussed a study which focused on increasing colorectal screening rates among patients in ethnic minority communities.

In a phase 1/2 study, THE-630 is displaying preliminary anti-tumor activity and tolerable safety in patients with advanced gastrointestinal stromal tumors.